# How I Diagnose Angioimmunoblastic T-Cell Lymphoma

Yi Xie, MD, PhD,[1,©] and Elaine S. Jaffe, MD[2]

From the [1]Department of Laboratory Medicine, University of California San Francisco School of Medicine, San Francisco, CA, USA; and [2]Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

**Key Words:** Angioimmunoblastic T-cell lymphoma; Peripheral T-cell lymphoma; Immunohistochemistry; Molecular diagnosis

## ABSTRACT

**Objectives:** *Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma derived from T-follicular helper cells. For pathologists, diagnosing AITL may be challenging due to its wide clinical and histopathologic spectrum, which can mimic a variety of reactive and neoplastic processes.*

**Methods:** *We summarize and discuss the clinicopathologic features of AITL, emphasizing diagnostic tools available to the practicing pathologist. Common diagnostic dilemmas are discussed.*

**Results:** *AITL exhibits various histologic patterns and is often associated with a prominent microenvironment that can obscure the neoplastic cells. Atypical B-cell proliferations, which can take a number of forms, are common in AITL, and clonal B-cell expansion can be seen. The atypical B cells can closely resemble Hodgkin/Reed-Sternberg cells, leading to misdiagnosis as classic Hodgkin lymphoma. Molecular studies have revealed recurrent genetic alterations, which can aid in differential diagnosis, particularly in problematic cases.*

**Conclusions:** *Given the complex diagnostic challenges in AITL, an integrated approach, incorporating clinical, morphologic, immunophenotypic, and molecular findings, is helpful to reach an accurate diagnosis.*

### Key points

- Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma of T-follicular helper cell origin featuring a broad spectrum of clinical and pathologic manifestations and distinct molecular characteristics.
- B-cell or plasma cell expansion is common in AITL, in some cases leading to misinterpretation as B-cell lymphoma or classic Hodgkin lymphoma.
- The diagnosis of AITL requires careful integration of clinical history, morphologic findings, and immunophenotypic findings, supplemented by molecular/genetic analysis as necessary.

Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma (PTCL) with unique clinicopathologic and genetic features. While AITL accounts for only 1% to 2% of all non-Hodgkin lymphomas, it is the second most common subtype of PTCL, representing approximately 15% to 20% of all PTCLs.[1-3] When first described, it was considered an abnormal immune reaction or atypical lymphoid hyperplasia.[4,5] Subsequent identification of cytogenetic abnormalities and clonality of the T cells led to the current view of AITL as a T-cell lymphoma.[6-8] Over the past two decades, advances in gene expression profiling and next-generation sequencing technologies have brought tremendous progress in our understanding of AITL. Today, AITL is recognized as a neoplasm derived from T-follicular helper (TFHs) cells, a finding that links together many of its clinical and pathologic features.[9,10] Studies have also identified follicular T-cell lymphoma (FTCL) and other nodal PTCLs with phenotypic and molecular overlap with AITL.[11-13] These lymphomas are now grouped with AITL in the 2016 revised World Health Organization (WHO) classification in the new category of nodal T-cell lymphoma of TFH-cell origin.[14]

Despite these advances, diagnosis of AITL in many instances remains challenging. Due to the functional properties of the neoplastic TFH cells, the lymphoma is polymorphic and contains variable proportions of tumor cells and inflammatory cells. The neoplastic T cells often constitute a minor part of the cellular infiltrate and may be difficult to identify. Moreover, concomitant expansion of B cells or other immune cells may simulate diverse reactive and neoplastic conditions. The histopathologic spectrum of AITL is broad, and sometimes morphologic features can be misleading. Some borderline lesions may pose a challenge to even experienced pathologists. This article summarizes clinical and pathologic features of AITL, with particular emphasis on commonly encountered problems and unique aspects of AITL that may aid in accurate diagnosis.

## Case Presentations

### Case 1

The patient is a 71-year-old woman with generalized lymphadenopathy. She had a history of polymyalgia rheumatica and had been treated with low-dose steroids for 2 years. A biopsy of an axillary lymph node was performed. Flow cytometry disclosed an atypical T-cell population that was positive for CD2, CD4, CD5, and CD7, with loss of surface CD3, and negative for CD8. Forty-five percent of the T cells were positive for CD10. H&E-stained sections showed a diffuse infiltrate of atypical lymphoid cells, effacing nodal architecture ▮Figure 1▮. Focal follicles with regressive changes were present. The paracortex showed prominent vascularity, with high endothelial venules exhibiting an arborizing pattern. While some cells resembling Hodgkin/Reed-Sternberg (HRS) cells were present, the atypia in the background lymphocytes argued against a diagnosis of classic Hodgkin lymphoma (CHL). As noted, flow cytometry suggested an abnormal phenotype with loss of surface CD3 and expression of CD10. The atypical lymphocytes were also positive for PD1 and ICOS, confirming a TFH phenotype. The HRS-like cells were positive for Epstein-Barr virus (EBV) and were rosetted by the atypical TFH population. A diagnosis of T-cell lymphoma was confirmed by clonal rearrangement of T-cell receptor genes by polymerase chain reaction (PCR). In this case, the differential diagnosis would include nodal PTCL with TFH phenotype vs AITL. Two features favor AITL in the present case: the marked expansion of CD21 dendritic cells enveloping clusters of the atypical lymphocytes and the presence of EBV-positive B cells.

### Case 2

The patient is a 63-year-old woman with a several-month history of cervical and submandibular lymphadenopathy with night sweats and fever. The patient had anemia (hematocrit, 22%; hemoglobin, 71 g/L) with normal WBC count and normal platelets. She exhibited polyclonal hypergammaglobulinemia (85 U/L) and moderately elevated lactic dehydrogenase (LDH) (326 U/L). EBV viral load was detected at 420 copies/mL. Chest computed tomography showed bilateral pleural effusions and widespread lymphadenopathy affecting axillary, paratracheal, and para-aortic lymph nodes, as well as hepatosplenomegaly. A cervical lymph node biopsy was performed.

H&E sections of the lymph node ▮Figure 2▮ showed numerous follicles with germinal centers displaying a starry sky pattern. The reactive germinal centers appeared to lack well-formed mantle cuffs and instead were surrounded by medium-sized to larger lymphoid cells with clear cytoplasm and vesicular nuclei. Admixed plasma cells were present in the interfollicular region. Increased vascularity was noted in the paracortex. Immunohistochemical stains were performed for CD20, CD79a, CD3, CD4, CD8, CD10, PD1, ICOS, CD21, and IgD. Epstein-Barr virus-encoded small RNAs (EBER) in situ hybridization for EBV was performed. The IgD stain confirmed the absence of a normal mantle cuff. Instead, the germinal centers were encircled by an atypical T-cell population that was positive for PD1, ICOS, and CD10. The atypical T cells were positive for CD3 and CD4. CD21 showed follicular dendritic cell (FDC) meshworks largely confined to the follicles. EBER was positive in scattered cells in the interfollicular region (10-20/high-power field). PCR studies were performed. These confirmed a clonal rearrangement pattern for T-cell receptor γ genes and a polyclonal IG rearrangement pattern.

A diagnosis of AITL pattern I was made based on these findings. AITL pattern I can be mistaken for atypical follicular hyperplasia. A clue in the current case on H&E was the absence of well-formed mantle cuffs. Cytologic atypia was readily seen on immunohistochemical stains. AITL pattern I often lacks the FDC expansion seen in more advanced cases. Evolution of AITL pattern I to patterns II to III has been shown in patients with sequential biopsies.[15]

## Clinical Features

AITL primarily affects middle-aged and elderly adults, with a median age in the fifth to sixth decades.[16] There is a slight male predominance.[17] Most patients have advanced-stage disease (stages III-IV).

**❚Figure 1❚** Angioimmunoblastic T-cell lymphoma with Epstein-Barr virus (EBV)–positive Hodgkin/Reed-Sternberg (HRS)–like cells. **A**, H&E shows a diffuse infiltrate of small- to medium-sized lymphoid cells with scattered admixed plasma cells. Prominent high endothelial venules were present. Scattered cells resembling HRS-like cells are present (×400). **B**, CD21 shows expanded dendritic cells that envelope clusters of atypical lymphoid cells (×200). The lymphoid cells are positive for CD4 (**C**, x400) and CD10 (**D**, x400).

Extranodal involvement is common. Characteristic features at presentation include constitutional symptoms, generalized lymphadenopathy (typically <1-3 cm), hepatosplenomegaly, and skin rash.[18] A significant proportion of patients also have pleural effusions and/or ascites. Bone marrow involvement has been reported in up to 70% of the cases.[19] Involvement of other extranodal sites such as lung and gastrointestinal tract can be seen but is less common.[20,21]

In addition to lymphoma-associated symptoms, many patients have immune dysregulation, resulting in autoimmune complications and immunodeficiency. There is usually polyclonal hypergammaglobulinemia and Coombs-positive hemolytic anemia.[22] Polyarthritis, vasculitis, and thyroid abnormalities are common. Laboratory tests frequently reveal circulating immune complexes, autoantibodies, cold agglutinins, elevated LDH, and hematologic abnormalities such as anemia, lymphopenia, thrombocytopenia, or eosinophilia.[23] Some patients may show evidence of immunodeficiency with opportunistic infections.[24] AITL may have a waxing and waning course, but it is generally aggressive, with a

**Figure 1** (cont) CD30 is positive in the HRS-like cells (**E**, x400), many of which are also positive for CD15 (**F**, x400). CD30 staining also highlights a subset of atypical lymphoid cells. The HRS-like cells are positive for EBV by EBER in situ hybridization (**G**, x400) and PAX5 (**H**, x200) and exhibit variation in morphology.

median survival of 3 years and a 5-year overall survival rate of approximately 30%.[23]

## Morphology and Immunohistochemistry

Lymph nodes involved by AITL typically show partial or complete architectural effacement with perinodal extension, but peripheral cortical sinuses are often spared. The infiltrate is usually diffuse or paracortical, composed of a polymorphous population of small- to medium-sized lymphocytes, scattered immunoblasts, histiocytes, plasma cells, and eosinophils amid prominent networks of arborizing high endothelial venules (HEVs). Follicles are typically regressed or absent, but there is a proliferation of FDCs in extrafollicular regions, often surrounding the HEVs.[25] The neoplastic T cells are usually small to medium in size with clear cytoplasm, clustering around HEVs and enwrapped by FDC meshworks.[26] In some cases, the neoplastic cells may be sparse or lack overt cytologic atypia or distinct clear cell morphology. Some cases may contain numerous large B immunoblasts or abundant plasma cells, obscuring the tumor cell population. Multinucleated HRS-like cells may be seen.[27] There are rare cases rich in epithelioid histiocytes, resembling granulomatous reaction or lymphoepithelioid lymphoma. In other cases, there may be a relatively monotonous proliferation of atypical lymphocytes with

**Figure 2** Angioimmunoblastic T-cell lymphoma pattern I. **A**, Reactive germinal center is surrounded by atypical cells with clear cytoplasm and immunoblastic features. High endothelial venules surround the atypical follicular structure (×100). **B**, The perifollicular cells have clear cytoplasm; admixed plasma cells are present (×400). **C**, CD20 highlights the germinal centers and scattered interfollicular B cells (×40). **D**, PD1 is strongly positive in the perifollicular T cells (×40).

sparse inflammatory component, simulating PTCL, not otherwise specified.[28]

Three overlapping histologic patterns have been described in AITL[29] **Table 1**. Most cases fall into histologic patterns II and III, with the typical morphologic features as described above. In pattern II, there are occasional regressed follicles, while pattern III is characterized by complete architectural effacement with no residual B-cell follicles.[29] The type I pattern is less common but can be particularly difficult to identify. Often, the lymph nodes show largely retained architecture with hyperplastic follicles, imparting an overall reactive appearance.[25,30] The follicles usually have ill-defined borders with attenuated

or obliterated mantle zones surrounded by a rim of atypical clear cells. In less obvious cases, the tumor cells may be inconspicuous and are best recognized by immunohistochemical study. Progression of patterns I to III has been documented in sequential biopsy specimens and is thought to represent morphologic evolution rather than clinical progression of the disease.[15,25]

Immunohistochemistry of the lymph node shows expansion of the paracortex by a diffuse infiltrate of T cells. The B-cell areas are often reduced and sometimes compressed in the far cortex of the lymph node, which can be a helpful clue to the diagnosis of AITL. Scattered large B blasts, often CD30+ and EBV+, are frequently found

▌**Figure 2**▌ (cont) Perifollicular T cells show cytologic atypia seen with CD3 (**E**, x400). **F**, A CD21 stain shows well-formed follicular dendritic cell meshworks within the follicles but no expansion in the paracortex (×400).

among the T-cell infiltrate.[31] FDC markers, CD21 and CD23, typically highlight extensive FDC meshworks outside of the follicles. However, in some cases, the abnormal FDC pattern may be focal. In AITL with type I pattern, CD21 and CD23 usually show only subtle sprouts of FDCs extending beyond the germinal centers. The expanded dendritic cells may actually represent fibroblastic reticular cells, which are a lineage closely related to FDC and can upregulate expression of CD21 and CD23. These "pre-FDCs" arise in a perivascular location.[32]

Immunohistochemical assessment of the tumor cell phenotype plays a key role in the diagnosis of AITL. Immunophenotypically, the neoplastic cells are T-cell receptor (TCR) α/β T cells with expression of pan–T-cell markers (eg, CD2, CD3, and CD5), although aberrant loss or downregulation of one or more T-cell markers (commonly CD3, CD5, or CD7) is frequently observed.[33] By flow cytometry, loss of surface CD3 is very commonly seen and can be a clue to the diagnosis.[34] In a subset of the cases, the cells may show partial expression of CD30. The neoplastic cells are usually CD4+ and also express multiple TFH-related antigens, including PD1/CD279, CD10, BCL6, CXCL13, ICOS, SAP, c-MAF, CD200, and CXCR5.[9,29,35-39] It is important to note that these markers are not always specific, and conversely, not all TFH markers can be detected in an otherwise typical case of AITL. Moreover, attention should be paid to the intensity and distribution of TFH markers, and staining pattern should correlate with morphology. Because reactive paracortical T cells with weak and variable expression of PD1 are almost invariably present, only strong staining

of PD1 is diagnostically useful.[40,41] CD10 is usually positive in only a small subset of the neoplastic cells and may show variable staining intensity. Among the TFH markers, PD1/CD279 and ICOS are reported to be most sensitive, whereas CXCL13 and CD10 are less sensitive but more specific.[42] As such, the 2016 WHO classification suggests that at least two (ideally three) TFH markers be expressed by the neoplastic cells to diagnose a case of PTCL as having a TFH phenotype.[43] ▌Table 2▌ summarizes immunohistochemical markers commonly used to diagnose AITL in routine clinical practice.

Possibly owing to the inherent function of the neoplastic cells as TFH, AITL is frequently accompanied by a proliferation of B cells. Findings that can be seen include polyclonal or clonal proliferation of large B cells, HRS-like cells, and plasma cells, which can be positive or negative for EBV. Studies have reported that more than 80% of AITLs contain a variable number of EBV-positive B cells, ranging from isolated or small clusters of B immunoblasts to focally confluent EBV-positive large B cells.[31,44] This proliferation may be so marked as to suggest a diagnosis of EBV-positive diffuse large B-cell lymphoma (DLBCL), either at initial diagnosis or during disease course.[15,44,45] Alternatively, the EBV-positive B cells may resemble HRS cells both morphologically and phenotypically, leading to a mistaken diagnosis of CHL.[27,46] The expansion of EBV-infected cells was thought to be related to defective immune surveillance for EBV.[24] However, rare cases with EBV-negative HRS-like cells have also been reported, suggesting other mechanisms for the abnormal B-cell proliferation.[46] As discussed below, the B cells in

**◼Table 1◼**

**Comparison of the Three Histologic Patterns of AITL**

| | Pattern I | Pattern II | Pattern III |
|---|---|---|---|
| Nodal architecture | Largely preserved | Partially or largely effaced | Completely effaced |
| B-cell follicles | Hyperplastic follicles with attenuated mantle cuffs | Scattered follicles, usually with regressive changes | Largely absent, atretic follicles confined to far cortex |
| FDC meshwork | No significant expansion or minimal expansion of FDCs around germinal centers | Prominent extrafollicular proliferation of FDCs, usually surrounding HEVs | Irregular proliferation of FDCs, usually surrounding HEVs |
| Neoplastic cells | Atypical T cells with predominantly perifollicular distribution | Aggregates of atypical T cells within the paracortex | Large aggregates or sheets of atypical T cells |
| Background | Perifollicular polymorphic infiltrate | Polymorphic paracortical infiltrate, HRS-like cells may be present | Diffuse polymorphic infiltrate, HRS-like cells may be present |

AITL, angioimmunoblastic T-cell lymphoma; FDC, follicular dendritic cell; HEV, high endothelial venule; HRS, Hodgkin/Reed-Sternberg.

**◼Table 2◼**

**Common Markers Used for Diagnosis of AITL**

| Markers | Utility | Comment |
|---|---|---|
| CD20 and PAX5 | Identify B-cell follicles, the distribution, proportion, and cytologic features of B cells in the infiltrate | B immunoblasts and HRS-like cells are variably positive for CD20 and PAX5 |
| CD3 | Access the distribution, proportion, and cytologic features of T cells in the infiltrate; identify T cells with cytologic atypia and/or altered expression of pan–T-cell antigens | Dim expression or loss of surface CD3 is found in a subset of AITL |
| CD2, CD5, and CD7 | Identify T cells with cytologic atypia and/or altered expression of pan–T-cell antigens | Loss of CD7 is common in AITL |
| CD4 and CD8 | Access the distribution, proportion, and cytologic features of T-cell subsets | Atypical T cells are CD4+ in >90% of AITLs |
| CD21 and CD23 | Identify FDC meshworks underlying follicles and extrafollicular proliferation of FDC meshworks, usually around HEVs | CD21 is generally more sensitive than CD23 |
| CD10 | Highlight reactive germinal centers; help identify atypical T cells with a TFH phenotype | Less sensitive but more specific. CD10 is often weak, heterogeneous, and confined to a small subset of the atypical T cells |
| BCL6 | Highlight reactive germinal centers; help identify atypical T cells with a TFH phenotype | Less sensitive but more specific |
| PD1 | Help identify atypical T cells with a TFH phenotype | Very sensitive but less specific; strong PD1 is more specific than weak staining |
| ICOS | Help identify atypical T cells with a TFH phenotype | Very sensitive (>90% sensitivity) but less specific |
| CXCL13 | Help identify atypical T cells with a TFH phenotype | Less sensitive but more specific; cytoplasmic staining with a perinuclear dot pattern |
| CD30 | Highlight B immunoblasts and HRS-like cells; may highlight a subset of the atypical T cells | CD30+ atypical T cells can be found in 20% to 30% of AITLs |
| κ and λ | Evaluate for light chain restriction in plasma cells | Polytypic plasmacytosis is common; monotypic plasma cells can be found in rare cases |
| EBV ISH | Identify EBV-positive B blasts | Varying numbers of EBV-positive cells can be found in 80% to 90% of AITLs |

AITL, angioimmunoblastic T-cell lymphoma; EBV, Epstein-Barr virus; FDC, follicular dendritic cell; HEV, high endothelial venule; HRS, Hodgkin/Reed-Sternberg; ISH, in situ hybridization; TFH, T follicular helper.

AITL may harbor mutations in *TET2*, similar to the neoplastic T cells, suggesting possibly common mutational events in a hematopoietic stem cell.[47,48]

AITL is also often associated with plasmacytosis.[49,50] Sometimes the plasma cells may be abundant, obscuring the underlying neoplastic T cells.[50] In rare instances, patients may have marked peripheral blood and/or bone marrow plasmacytosis.[19,51,52] The plasma cell expansions in AITL are thought to result from the increased release of cytokines such as interleukin (IL)–6 or IL-10.[53] The plasma cells in most cases are polyclonal and EBV negative, but clonal plasma cell proliferations also have been reported.[49,50]

## Skin and Bone Marrow Involvement

In addition to lymph nodes, skin and bone marrow involvement by AITL is also frequent. The histologic findings of AITL involving skin are subtle histologically.[54] Skin biopsy specimens often show mild perivascular or periadnexal lymphoid infiltrates that may be difficult to

differentiate from inflammatory conditions. Characteristic features of nodal AITLs, such as clear cells, vascular hyperplasia, and EBV-positive cells, are seen in only a minority of cases.[55] Immunohistochemistry for TFH markers may be helpful to identify the neoplastic cells, and PCR studies have identified a monoclonal T-cell population in more than 80% of cases.[54,56] However, it is important to note that a TFH immunophenotype is not entirely specific for AITL, and it can also be seen in primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder and other cutaneous T-cell lymphomas.[54] Correlation with clinical history and lymph node pathology is essential in these cases, as the skin biopsy specimen alone is usually not definitive.

In bone marrow, AITL usually shows single or multiple loose nodular lymphoid infiltrates with a paratrabecular or interstitial distribution pattern.[19,51,57] The infiltrate is often polymorphic, composed of many small or scattered larger lymphocytes, histiocytes, variable eosinophils, and, occasionally, aggregates of clear cells. Various secondary changes such as trilineage hematopoietic hyperplasia, polyclonal plasmacytosis, and myelofibrosis may be present. Immunohistochemical studies have shown a more subtle expression of the TFH markers in the bone marrow than lymph node. Nevertheless, immunohistochemical staining of the TFH markers, such as PD1, BCL6, and CXCL13, can still be helpful for detecting lymphomatous infiltrates. In addition, it has been recognized that most cases of AITL display a unique sCD3(–/dim)/CD4+/CD10 variable phenotype by flow cytometry.[34,58,59] Thus, flow cytometry is an effective tool in identifying small populations of aberrant T cells and can assist in diagnosis and monitoring of AITL, particularly in fluid specimens such as peripheral blood and bone marrow.[34,58]

## Molecular and Genetic Features

Most AITLs show clonal or oligoclonal rearrangement of the T-cell receptor genes. In addition, clonal and oligoclonal rearrangements of the B-cell receptor genes are found in up to 50% of cases, in part due to the expansion of EBV+ B cells.[60] By conventional cytogenetic analysis, clonal abnormalities, most commonly trisomy 3, trisomy 5, trisomy 21, additional X chromosome, and loss of 6q, are detected in approximately 70% of AITL cases.[61,62] The t(5;9)(q33;q22);*ITK-SYK*, which is reported in around 20% of follicular T-cell lymphomas, has been identified infrequently in AITL.[12,63,64]

In the past two decades, significant progress has been made in understanding the pathobiology and pathogenesis of AITL. The tumor cells in AITL are recognized to originate from TFH cells based on gene expression profiling.[9,10] Whole-exome sequencing and targeted sequencing studies have identified a group of recurrent mutations, including genes encoding the epigenetic regulators, *TET2* (50%-80%), *DNMT3A* (20%-30%) and *IDH2* (20%-45%), the small GTPase, *RHOA* (50%-70%), and the components of the TCR signaling pathways such as *PLCG1* (14%), *CD28* (9%-11%), *FYN* (3%-4%), and *VAV1* (5%).[65-71] Among these mutations, the $RHOA^{G17V}$ mutation, present in up to 70% of AITLs, is also commonly observed in other T-cell lymphomas with the TFH phenotype but is seldom detected in other cancers.[48,69,71,72] Therefore, it is considered a hallmark and genetic indicator for TFH lymphoma. In contrast, the $IDH2^{R172}$ mutation, occurring at a frequency of 20% to 30%, is found in AITL and is rare in other PTCLs with the TFH phenotype.[70,72]

Importantly, studies have shown that *TET2* and *DNMT3A* mutations are not restricted to T cells but can also be identified in the admixed mature B cells in the lymph nodes and the hematopoietic stem cells of patients with AITL, whereas *RHOA* and *IDH2* mutations appear confined to the neoplastic T cells.[66,73,74] In light of these and some other findings, a multistep and multilineal tumorigenesis has been suggested, in which initial epigenetic deregulation (*TET2*, *DNMT3A*) occurring in hematopoietic stem cells in cooperation with subsequent mutations in genes important for T-cell function (*RHOA*, *VAV1*, *PLCG1*, *CD28*, and others) leads to AITL.[72] Interestingly, previous studies have shown that clonal hematopoiesis (CH) and myeloid neoplasms such as chronic myelomonocytic leukemia and acute myeloid leukemia are more frequent in patients with AITL than in the general population.[75] In some patients, the myeloid neoplasms and AITL share common ancestral mutations in *TET2* and/or *DNMT3A*, suggesting that they arise from divergent evolution of a common CH clone.[76,77] Moreover, Nguyen et al[74] recently reported that in addition to *TET2* and *DNMT3A* mutations, the B cells in AITL lymph nodes can acquire additional B-cell–specific mutations in *NOTCH1* and other genes, which may account for the frequent occurrence of clonal B-cell expansion in AITL.

## Other Nodal Peripheral T-Cell Lymphoma With TFH Phenotype

In addition to AITL, the 2016 revised WHO classification included two provisional entities of PTCL-TFH, namely, FTCL and nodal PTCL with a TFH phenotype. In FTCL, lymph nodes typically show a

predominantly nodular/follicular growth pattern, mimicking follicular lymphoma. The neoplastic T cells tend to form small aggregates dispersed in the B-cell nodules.[12] These lesions may contain EBV-positive or EBV-negative HRS-like cells but usually do not have a prominent inflammatory background and lack proliferation of HEVs or extrafollicular expansion of FDC meshworks.[46] Despite morphologic differences, the immunophenotypic and molecular features overlap with AITL.[11] Furthermore, there are a few reports of patients with typical features of AITL at initial presentation but FTCL in subsequent biopsy specimens or vice versa, suggesting that these entities may represent variations along the spectrum of a common disease.[12]

## Diagnostic Challenges

Accurate diagnosis of AITL can be difficult due to its diverse clinical symptoms and wide histopathologic changes, which can mimic a variety of benign and malignant lymphoid proliferations ❙Table 3❙. One of the common challenges is identifying "early" AITL cases (type I pattern) and separating them from reactive paracortical hyperplasia. In addition, B-cell proliferations that accompany AITL may also pose a challenge in the differential diagnosis. In particular, the presence of HRS-like cells may lead to misdiagnosis as CHL. Distinguishing AITL from other nodal PTCL-TFHs can be particularly difficult, although it currently has no impact on clinical management. Given the complex heterogeneous nature of AITL, a multiparameter approach with careful integration of clinical history, morphology, and immunophenotypic findings, supplemented by molecular/genetic analysis as necessary, is essential to make an accurate diagnosis. In the next section, we discuss some of the most common questions about the diagnosis and differential diagnosis of AITL.

### Questions for the Experts

1. How do we distinguish AITL with a type I pattern from reactive paracortical hyperplasia?

A significant proportion of AITL cases (up to 17%) present histologically with the type I pattern (also called "early" pattern).[29,30] The distinction between type I AITL and reactive paracortical (T-zone) hyperplasia can be challenging due to their overlapping morphologic features.[29] As mentioned earlier, AITL pattern I usually comprises hyperplastic follicles with ill-defined borders and attenuated mantle zones. While the presence of atypical clear cells at the outer rim of the germinal centers favors AITL, in many cases, the atypical cells may be inconspicuous, and morphologic findings alone are insufficient to signify a correct diagnosis.

Immunohistochemical staining for the TFH cell markers, particularly PD1, is of great value in distinguishing AITL type I with reactive paracortical hyperplasia. In paracortical hyperplasia, strong PD1-positive cells are confined to the germinal centers (primarily to the light zone at the periphery of germinal centers), although there may be scattered or sometimes numerous extrafollicular T cells with variable and weak PD1 positivity.[40] In contrast, PD1 demonstrates a strong perifollicular staining pattern in AITL, corresponding to the "perifollicular" distribution of neoplastic TFH cells. Markers such as CD10, if strongly expressed in perifollicular T cells, are a helpful clue. Expansion of CD21+ meshworks with a perivascular distribution, seen in pattern II or III, is usually not evident in pattern I. The presence of interfollicular EBV-positive B blasts is also helpful but may not be a distinguishing feature, as it can also be seen in acute and chronic EBV infection as well as other lymphoproliferative disorders.

Clinical features have particular importance in the diagnosis of AITL. Interestingly, despite early involvement (pattern I) histologically, many patients reportedly had clinically advanced disease.[15] Caution should be exercised in cases that lack characteristic clinical symptoms. If an early AITL is suspected, clonality studies should be obtained. The findings of clonal T-cell gene rearrangement, with or without concurrent B-cell gene rearrangement, are helpful in confirming a diagnosis of AITL. As always, the final diagnosis should be based on both the clinical and pathologic features as well as the molecular findings. In equivocal cases, close follow-up and repeat biopsy are recommended to establish a definitive diagnosis.

2. Where should we draw the line between B-cell proliferation in AITL and so-called composite lymphoma?

As mentioned previously, the presence of large B cells, often with immunoblastic features, usually but not always infected by EBV, is a characteristic feature of AITL.[46] These cells are typically scattered in the interfollicular zone, sometimes showing an HRS-like appearance.[27] However, in some cases, there may be prominent expansion of EBV-positive B cells, forming large clusters to confluent foci of large transformed B cells, focally obscuring the coexisting T-cell component.[44] B-cell proliferation may progress, and so-called secondary large B-cell lymphomas have been reported in a few cases, occurring simultaneously or before the initial diagnosis of AITL or, more commonly, at relapse.[44,45]

**Table 3**
**Differential Diagnosis of AITL**

| Entity | Confusing Features | Features Favoring Diagnosis of Entity | Features Favoring Diagnosis of AITL |
|---|---|---|---|
| Reactive paracortical hyperplasia | Paracortical expansion Immunoblastic proliferation Extrafollicular T cells with variable and weak PD1 positivity Increased vascularity | No definite cytologic atypia Strong CD10 or PD1-positive cells are confined to the germinal centers No FDC meshwork outside germinal centers No clonal rearrangement | Atypical clear cells at the outer rim of the germinal centers or around HEVs TFH markers such as CD10 and PD1 are strongly expressed on interfollicular or perifollicular atypical T cells FDC meshwork outside germinal centers EBV-positive immunoblasts and HRS-like cells Oligoclonal or monoclonal TCR rearrangement Monoclonal IG rearrangement sometimes present |
| Classic Hodgkin lymphoma | HRS-like cells, frequently EBV positive Polymorphic background | Bands of fibrosis Nodular growth pattern No atypical T-cell population TFH markers highlight a single layer of reactive T cells forming rosettes around HRS cells CD30 staining restricted to the HRS cells No clonal TCR rearrangement | Open peripheral sinuses; prominent arborizing HEVs TFH markers highlight aggregates of atypical T cells surrounding the HRS-like cells The neoplastic T cells may express variable CD30 Monoclonal TCR rearrangement |
| Peripheral T-cell lymphoma, NOS | Atypical T-cell population with frequent loss of T-cell antigens | Lack of characteristic TFH phenotype Lack of extrafollicular FDC meshwork or prominent arborizing HEVs | Polymorphous infiltrate; Extrafollicular FDC meshwork Prominent arborizing HEVs Expression of at least two (ideally three) TFH markers Occasional EBV-positive immunoblasts |
| Diffuse large B-cell lymphoma | Large B-cell proliferation Monoclonal IG rearrangement | Cohesive sheets of large B cells No atypical T-cell population in the background No clonal TCR rearrangement | Atypical T cells with TFH phenotype in the background Extrafollicular FDC meshwork Prominent arborizing HEVs Monoclonal TCR rearrangement |
| Nodal marginal zone lymphoma | B-cell proliferation Monoclonal plasma cells may be present Extrafollicular T cells with variable and weak PD1 positivity Monoclonal IG rearrangement | No atypical T-cell population in the background No clonal TCR rearrangement | Atypical T cells with TFH phenotype in the background Extrafollicular FDC meshwork Monoclonal TCR rearrangement EBV-positive immunoblasts and HRS-like cells |

AITL, angioimmunoblastic T-cell lymphoma; EBV, Epstein-Barr virus; FDC, follicular dendritic cell; HEV, high endothelial venules; HRS, Hodgkin/Reed-Sternberg; IG, immunoglobulin; NOS, not otherwise specified; TCR, T-cell receptor; TFH, T follicular helper.

Moreover, there are rare reports of AITL and DLBCL in the same anatomic site, so-called composite AITL and large B-cell lymphoma.[78,79] Our own clinical experience suggests that that prognosis is dominated by AITL and that the EBV-positive B-cell expansions are less significant clinically. Given the B-cell expansion in AITL, rituximab had been incorporated into clinical treatment protocols, but long-term clinical benefit was not shown for this approach.[80] Therefore, a diagnosis of "composite" lymphoma is generally not made in these cases. Recent data have found shared mutations within the B cells and T cells in some cases of AITL, raising the possibility that AITL arises in a pluripotent stem cell. These observations are provocative but require further investigation to decipher the clonal relationship of the B cells and T cells within AITL.

3. How many TFH markers are needed for the diagnosis of AITL, and which ones need to be done routinely?

Since being recognized in the 1970s, several immunohistochemical and flow cytometric markers have been reported that could aid in the identification of neoplastic TFH cells in AITL. These include surface markers PD1, CD10, CD200, ICOS, and cytoplasmic SAP; transcription factor BCL6 and c-MAF; the chemokine CXCL13 and its receptor CXCR5; and so on.[9,29,35-39]

Among TFH markers, PD1 and ICOS are more sensitive for identifying the neoplastic TFH cells, whereas CXCL13 and CD10 are more specific.[42] However, none of the TFH markers in isolation is 100% sensitive or specific for the TFH phenotype. For this reason, the 2016 WHO requires demonstrating expression of at least two but ideally three TFH markers to establish a diagnosis of TFH lymphoma.[14] We routinely perform CD10, BCL6, ICOS, and PD1 stains on all cases and additional TFH markers such as CXCL13 when necessary. Basha et al[81] recently evaluated the utility of a five-marker TFH panel (CD10, BCL6, PD1, CXCL13, and ICOS) for the diagnosis of AILT and PTCL-TFH. They showed that while a four-marker panel (CD10, BCL6, PD1, CXCL13) was adequate to diagnose most AITLs, a five-marker panel with the addition of ICOS significantly increased the ability to identify PTCL-TFH. A significant issue is intensity, since many of these markers (PD1, ICOS) can be dimly positive, a feature with less specificity. With CD10, the number of positive cells may be only few, but if they are cytologically atypical, even few positive cells are relevant. It is important to bear in mind that AITL is based on a constellation of clinical and pathologic features. In a classic case, with expansion of FDCs around the HEVs, arborizing vascular proliferation, and increased EBV-positive cells, fewer TFH markers may be required to reach a confident diagnosis of AITL.

4. How do we differentiate AITL and other PTCL of TFH derivation with HRS-like cells from classic Hodgkin lymphoma?

As mentioned earlier, HRS-like cells are common findings in lymphomas of TFH derivation, such as AITL and FTCL, and can assume both the morphology and immunophenotype of classic Reed-Sternberg cells of Hodgkin lymphoma.[46] As atypia in the background T-cell population may be minimal, a potential pitfall in the differential diagnosis of the lymphomas of TFH derivation is misdiagnosing CHL. This is especially so in FTCL, in which HRS-like cells are present in a background of small lymphocytes with a nodular growth pattern, closely mimicking lymphocyte-rich CHL.[82]

Like CHL, the HRS-like cells in PTCL-TFH are consistently positive for CD30 and show weak PAX5, often with coexpression of CD15, negative or variably positive for CD20. In PTCL-TFH, the HRS-like cells are commonly EBV infected, and in situ hybridization for EBER most often highlights a wider range of positive cells than seen in EBV-positive CHL; however, this is not always the case. The key to the correct diagnosis lies in the recognition of a background atypical T-cell component with

appropriate immunophenotypic and molecular studies. In FTCL, immunostaining characteristically highlights aggregates of small- to medium-sized, mildly atypical T cells with a TFH immunophenotype, surrounding the HRS-like cell. In contrast, TFH markers usually identify a single layer of reactive T cells forming rosettes around HRS cells in lymphocyte-rich CHL.[46,82] Accordingly, immunophenotyping by flow cytometry frequently detects a distinct CD3−/dim CD4+ T-cell population in AITL and FTCL but not in CHL, which may also provide a clue in the differential diagnosis.[34] In some cases of PTCL-TFH, the neoplastic T cells may also express variable CD30, whereas CD30 staining is typically restricted to the HRS cells in CHL. A common finding is clusters of atypical CD30+ or MUM1+ T cells surrounding the HRS-like cells. The findings of open peripheral sinuses, prominent arborizing HEVs, and extrafollicular FDC expansions are helpful features to suggest a diagnosis of AITL rather than CHL. While the correct diagnosis can generally be made based on morphologic and immunophenotypic findings, in difficult cases, molecular studies may be necessary to confirm the diagnosis.

## Conclusions

AITL is a neoplasm of TFH cells with a constellation of clinical symptoms and pathologic characteristics that can pose diagnostic challenges. An integrated approach, incorporating clinical, histologic, immunophenotypic, and molecular findings, is essential to reach an accurate diagnosis. The growing knowledge of the molecular underpinnings of TFH lymphoma has improved our understanding of its pathobiology and will continue to aid in the diagnosis, especially of problematic cases, leading to a more precise classification and, eventually, better therapeutic strategies for patients with PTCL-TFH.

## References

1. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol.* 2008;26:4124-4130.

2. de Leval L, Parrens M, Le Bras F, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. *Haematologica.* 2015;100:e361-e364.

3. Rüdiger T, Weisenburger DD, Anderson JR, et al; Non-Hodgkin's Lymphoma Classification Project. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. *Ann Oncol.* 2002;13:140-149.

4. Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy: a hyperimmune entity resembling Hodgkin's disease. *N Engl J Med.* 1975;292:1-8.

5. Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. *Lancet.* 1974;1:1070-1073.

6. Lipford EH, Smith HR, Pittaluga S, et al. Clonality of angioimmunoblastic lymphadenopathy and implications for its evolution to malignant lymphoma. *J Clin Invest.* 1987;79:637-642.

7. Weiss LM, Strickler JG, Dorfman RF, et al. Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. *Am J Pathol.* 1986;122:392-397.

8. Kaneko Y, Maseki N, Sakurai M, et al. Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive "angioimmunoblastic lymphadenopathy with dysproteinemia-type" features. *Blood.* 1988;72:413-421.

9. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. *Blood.* 2007;109:4952-4963.

10. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. *Cancer Res.* 2007;67:10703-10710.

11. de Leval L, Savilo E, Longtine J, et al. Peripheral T-cell lymphoma with follicular involvement and a CD4+/bcl-6+ phenotype. *Am J Surg Pathol.* 2001;25:395-400.

12. Huang Y, Moreau A, Dupuis J, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. *Am J Surg Pathol.* 2009;33:682-690.

13. Dobay MP, Lemonnier F, Missiaglia E, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. *Haematologica.* 2017;102:e148-e151.

14. Swerdlow SH, Campo E, Harris NL, et al, eds. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.* Rev. 4th ed. Lyon, France: IARC; 2017.

15. Attygalle AD, Kyriakou C, Dupuis J, et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. *Am J Surg Pathol.* 2007;31:1077-1088.

16. Mourad N, Mounier N, Brière J, et al; Groupe d'Etude des Lymphomes de l'Adulte. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. *Blood.* 2008;111:4463-4470.

17. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. *Br J Haematol.* 2010;148:673-689.

18. Lachenal F, Berger F, Ghesquières H, et al. Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. *Medicine (Baltimore).* 2007;86:282-292.

19. Cho YU, Chi HS, Park CJ, et al. Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. *Am J Clin Pathol.* 2009;131:640-646.

20. Bradley SL, Dines DE, Banks PM, et al. The lung in immunoblastic lymphadenopathy. *Chest.* 1981;80:312-318.

21. Kaneki T, Kawashima A, Akamatsu T, et al. Immunoblastic lymphadenopathy-like T-cell lymphoma complicated by multiple gastrointestinal involvement. *J Gastroenterol.* 1999;34:253-259.

22. Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characterstics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. *J Clin Oncol.* 2013;31:240-246.

23. Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. *Leuk Lymphoma.* 1999;32:545-552.

24. Dunleavy K, Wilson WH, Jaffe ES. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. *Curr Opin Hematol.* 2007;14:348-353.

25. Ree HJ, Kadin ME, Kikuchi M, et al. Angioimmunoblastic lymphoma (AILD-type T-cell lymphoma) with hyperplastic germinal centers. *Am J Surg Pathol.* 1998;22:643-655.

26. Willenbrock K, Renné C, Gaulard P, et al. In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population: a molecular single-cell and immunohistochemical study. *Virchows Arch.* 2005;446:15-20.

27. Quintanilla-Martinez L, Fend F, Moguel LR, et al. Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. *Am J Surg Pathol.* 1999;23:1233-1240.

28. Warnke RA, Jones D, Hsi ED. Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. *Am J Clin Pathol.* 2007;127:511-527.

29. Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. *Blood.* 2002;99:627-633.

30. Rodriguez-Justo M, Attygalle AD, Munson P, et al. Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. *Mod Pathol.* 2009;22:753-761.

31. Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. *Blood.* 1992;79:1789-1795.

32. Krautler NJ, Kana V, Kranich J, et al. Follicular dendritic cells emerge from ubiquitous perivascular precursors. *Cell.* 2012;150:194-206.

33. Lee SS, Rüdiger T, Odenwald T, et al. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. *Int J Cancer.* 2003;103:12-20.

34. Alikhan M, Song JY, Sohani AR, et al. Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(-/dim)CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. *Mod Pathol.* 2016;29:1173-1182.

35. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. *Am J Surg Pathol.* 2006;30:490-494.

36. Dorfman DM, Brown JA, Shahsafaei A, et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. *Am J Surg Pathol.* 2006;30:802-810.

37. Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? *Blood.* 2005;106:1501-1502.

38. Roncador G, García Verdes-Montenegro JF, Tedoldi S, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. *Haematologica.* 2007;92:1059-1066.

39. Bisig B, Thielen C, Herens C, et al. c-Maf expression in angioimmunoblastic T-cell lymphoma reflects follicular helper T-cell derivation rather than oncogenesis. *Histopathology.* 2012;60:371-376.

40. Krishnan C, Warnke RA, Arber DA, et al. PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. *Am J Surg Pathol.* 2010;34:178-189.

41. Egan C, Laurent C, Alejo JC, et al. Expansion of PD1-positive T cells in nodal marginal zone lymphoma: a potential diagnostic pitfall. *Am J Surg Pathol.* 2020;44:657-664.

42. Gaulard P, de Leval L. Follicular helper T cells: implications in neoplastic hematopathology. *Semin Diagn Pathol.* 2011;28:202-213.

43. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* 2016;127:2375-2390.

44. Zettl A, Lee SS, Rüdiger T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. *Am J Clin Pathol.* 2002;117:368-379.

45. Willenbrock K, Bräuninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. *Br J Haematol.* 2007;138:733-739.

46. Nicolae A, Pittaluga S, Venkataraman G, et al. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. *Am J Surg Pathol.* 2013;37:816-826.

47. Schwartz FH, Cai Q, Fellmann E, et al. *TET2* mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. *J Pathol.* 2017;242:129-133.

48. Fukumoto K, Nguyen TB, Chiba S, et al. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. *Cancer Sci.* 2018;109:490-496.

49. Balagué O, Martínez A, Colomo L, et al. Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. *Am J Surg Pathol.* 2007;31:1310-1322.

50. Huppmann AR, Roullet MR, Raffeld M, et al. Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation. *J Clin Oncol.* 2013;31:e28-e30.

51. Grogg KL, Morice WG, Macon WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. *Br J Haematol.* 2007;137:416-422.

52. Ahsanuddin AN, Brynes RK, Li S. Peripheral blood polyclonal plasmacytosis mimicking plasma cell leukemia in patients with angioimmunoblastic T-cell lymphoma: report of 3 cases and review of the literature. *Int J Clin Exp Pathol.* 2011;4:416-420.

53. Nagoshi H, Kuroda J, Kobayashi T, et al. Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis. *Int J Hematol.* 2013;98:366-374.

54. Oishi N, Sartori-Valinotti JC, Bennani NN, et al. Cutaneous lesions of angioimmunoblastic T-cell lymphoma: clinical, pathological, and immunophenotypic features. *J Cutan Pathol.* 2019;46:637-644.

55. Brown HA, Macon WR, Kurtin PJ, et al. Cutaneous involvement by angioimmunoblastic T-cell lymphoma with remarkable heterogeneous Epstein-Barr virus expression. *J Cutan Pathol.* 2001;28:432-438.

56. Ortonne N, Dupuis J, Plonquet A, et al. Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL). *Am J Surg Pathol.* 2007;31:1068-1076.

57. Gerlach MM, Juskevicius D, Vela V, et al. Bone marrow infiltration of angioimmunoblastic T-cell lymphoma: identification and prognostic impact of histologic patterns and diagnostic application of ancillary phenotypic and molecular analyses. *Arch Pathol Lab Med.* 2020;144:602-611.

58. Stacchini A, Demurtas A, Aliberti S, et al. The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas. *Am J Clin Pathol.* 2007;128:854-864.

59. Yuan CM, Vergilio JA, Zhao XF, et al. CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. *Hum Pathol.* 2005;36:784-791.

60. Tan BT, Warnke RA, Arber DA. The frequency of B- and T-cell gene rearrangements and Epstein-Barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. *J Mol Diagn.* 2006;8:466-475; quiz 527.

61. Schlegelberger B, Zhang Y, Weber-Matthiesen K, et al. Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics. *Blood.* 1994;84:2640-2648.

62. Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. *Br J Haematol.* 2003;121:681-691.

63. Streubel B, Vinatzer U, Willheim M, et al. Novel t(5;9) (q33;q22) fuses *ITK* to *SYK* in unspecified peripheral T-cell lymphoma. *Leukemia.* 2006;20:313-318.

64. Attygalle AD, Feldman AL, Dogan A. *ITK/SYK* translocation in angioimmunoblastic T-cell lymphoma. *Am J Surg Pathol.* 2013;37:1456-1457.

65. Cairns RA, Iqbal J, Lemonnier F, et al. *IDH2* mutations are frequent in angioimmunoblastic T-cell lymphoma. *Blood.* 2012;119:1901-1903.

66. Lemonnier F, Couronné L, Parrens M, et al. Recurrent *TET2* mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. *Blood.* 2012;120:1466-1469.

67. Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. *Blood.* 2014;123:1293-1296.

68. Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, *RHOA* and *FYN* kinase in peripheral T cell lymphomas. *Nat Genet.* 2014;46:166-170.

69. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic *RHOA* mutation in angioimmunoblastic T cell lymphoma. *Nat Genet.* 2014;46:171-175.

70. Wang C, McKeithan TW, Gong Q, et al. *IDH2R172* mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. *Blood.* 2015;126:1741-1752.

71. Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in *RHOA* GTPase in angioimmunoblastic T cell lymphoma. *Nat Genet.* 2014;46:371-375.

72. Mhaidly R, Krug A, Gaulard P, et al. New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. *Oncogenesis.* 2020;9:73.

73. Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer Cell.* 2011;20:25-38.

74. Nguyen TB, Sakata-Yanagimoto M, Asabe Y, et al. Identification of cell-type-specific mutations in nodal T-cell lymphomas. *Blood Cancer J.* 2017;7:e516.

75. Kommalapati A, Tella SH, Go RS, et al. A population-based analysis of second primary malignancies in T-cell neoplasms. *Br J Haematol.* 2019;185:338-342.

76. Tiacci E, Venanzi A, Ascani S, et al. High-risk clonal hematopoiesis as the origin of AITL and *NPM1*-mutated AML. *N Engl J Med.* 2018;379:981-984.

77. Lewis NE, Petrova-Drus K, Huet S, et al. Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. *Blood Adv.* 2020;4:2261-2271.

78. Xu Y, McKenna RW, Hoang MP, et al. Composite angioimmunoblastic T-cell lymphoma and diffuse large B-cell lymphoma: a case report and review of the literature. *Am J Clin Pathol.* 2002;118:848-854.

79. Hoffmann JC, Chisholm KM, Cherry A, et al. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. *Hum Pathol.* 2016;48:9-17.

80. Delfau-Larue MH, de Leval L, Joly B, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma: a clinicobiological study of the GELA. *Haematologica.* 2012;97:1594-1602.

81. Basha BM, Bryant SC, Rech KL, et al. Application of a 5 marker panel to the routine diagnosis of peripheral T-cell lymphoma with T-follicular helper phenotype. *Am J Surg Pathol.* 2019;43:1282-1290.

82. Moroch J, Copie-Bergman C, de Leval L, et al. Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics. *Am J Surg Pathol.* 2012;36:1636-1646.